http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
-
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
-
Pfizer (PFE) and Genmab (GMAB) Reports TIVDAK sBLA Accepted for Priority Review by FDA
-
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
-
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
-
Pfizer Declares First-Quarter 2024 Dividend
-
Pfizer (PFE) Completes Acquisition of Seagen (SGEN)
-
Pfizer Completes Acquisition of Seagen
-
Pfizer (PFE) Receives Approvals to Complete the Acquisition of Seagen
-
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
-
Pfizer (PFE) Announces FDA and EMA Acceped Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
-
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
-
Pfizer (PFE) Presents New Marstacimab Phase 3 Data Showing Significant Bleed Reduction in Hemophilia A and B
-
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
-
Pfizer (PFE) Announces European Commission Approves ELREXFIO for Relapsed and Refractory Multiple Myeloma
-
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
-
Arvinas (ARVN) and Pfizer (PFE) Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)
-
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
-
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
-
Pfizer (PFE) announced Phase 2B trial of danuglipron showed statistically significant reductions from baseline in body weight for all doses
-
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
-
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) and BioNTech (BNTX) Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
-
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
-
Pfizer (PFE) Announces FDA Approves PENBRAYA
-
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
-
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
-
Pfizer (PFE) Announces FDA Approval of VELSIPITY for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
-
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
-
Pfizer (PFE) Announces FDA Approval of BRAFTOVI + MEKTOVI for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
-
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
-
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
-
Pfizer Declares Fourth-Quarter 2023 Dividend
-
Ginkgo Bioworks (DNA) Announces Multi-Target RNA Discovery Collaboration with Pfizer (PFE)
-
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
-
Pfizer (PFE) Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO for RSV
-
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
-
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
